|
|
- Juliana Cobb
- 5 years ago
- Views:
Transcription
1
2
3
4
5
6
7
8
9
10
11 BUY ONE GENE, GET ONE 30 FREE! G E N E P A N E L T E S T I N G F O R H E R E D I T A R Y C A N C E R : G E T T I N G I T R I G H T
12 THIS COULD BE YOU ONE DAY SOON: Starting out in your new OB/Gyn practice You meet Lori, a new patient, for her annual well-woman visit:
13 LORI: 37-year old Caucasian female good general health family history: mother: HTN, osteopenia dx ed 65 father: colon polyps dx ed 68 PGM: breast cancer dx ed 55 sister: recently dx ed with breast cancer at 42
14 FUN FACT #1: F A M I LY H I S T O R Y W A S T H E F I R S T G E N E T I C T E S T.
15 CASE #1 LORI S PEDIGREE
16 Family histor Lifestyle y Cancer Risk Environmen t Gene s
17 FUN FACT #2: A L L C A N C E R I S G E N E T I C, BUT F E W C A N C E R S A R E I N H E R I T E D.
18 STAGES OF CANCER DEVELOPMENT Normal cell Mutation in Gene A Increased proliferation Mutation in Gene B Early neoplasia Mutation in Gene C Progressive neoplasia Carcinoma Continuing cascade of mutations Metastasis
19 ALL CANCERS HAVE GENETIC ORIGINS Somatic mutations Germline Mutations Occur in non-germline tissues (breast, colon, lung, blood, etc.) Not inherited sporadic Start out in egg and sperm cells Heritable Once inherited, mutation is present in all cells of the body 90-97% of all cancers 3-10% of all cancers
20 THE WORLD OF CANCER GENETIC TESTING Direct-to-consumer Tumor testing (somaticbased) Germline genetic testing
21 GERMLINE GENETIC TESTING WHO? WHY? Myriad, Ambry, GeneDx, Prevention, etc. WHAT? DNA sequencing and deletion/duplication analysis of genes associated with inherited cancer syndromes To guide screening, prophylaxis, risk management, and identify at-risk family members LIMITATIONS not every cancer risk gene is known possibility of unclear results cannot prevent / screen for all cancer risks more questions than answers anxiety / distress
22 CASE #1 LORI S PEDIGREE
23 NATIONAL COMPREHENSIVE CANCER NETWORK Mission statement: Our mission, as an alliance of leading cancer centers devoted to patient care, research, and education, is improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Clinical Practice Guidelines in Oncology Patient Guidelines CEU programs
24
25 NCCN GUIDELINES FOR HEREDITARY BREAST/OVARIAN ASSESSMENT personal history of ovarian cancer at any age personal history of breast cancer <45 triple negative breast cancer two primary breast cancers two or more family members with breast and/or ovarian cancer, especially <50
26
27 CONSIDER GENETIC TESTING BUT FOR WHO? Lori? Lori s sister?? Someone else???
28 FUN FACT #3: IDEALLY, GENETIC TESTING SHOULD BE PERFORMED ON AN AFFECTED INDIVIDUAL.
29 SO WHAT TESTING DO WE OFFER THIS FAMILY? Back in the day (<5 years ago), we had only a small handful of cancer genes we routinely tested for. Myriad Labs held the patent on the BRCA1 and BRCA2 genes and was the only lab who could do the testing. On June 13, 2013, the Supreme Court struck down the patent, ruling that genes are not patentable. On June 14, 2013, every genetic testing laboratory was offering BRCA1 / 2.
30 Introduction of NGS technologies
31
32 NGS MULTIGENE PANELS Benefits -- assess any number of genes at once (typically anywhere from 15 50) -- clarify patient s risk (and those of other carriers of familial variant) -- guide medical management Challenges -- turnaround time may be several weeks delayed decision-making -- limited literature on many genes / variants -- interpreting results for unaffected family members -- variants of unknown significance -- informed consent -- follow up in the case of variant reclassification
33 DISTRIBUTION OF PATHOGENIC VARIANTS IN HBOC FAMILIES Citation: Castera, L. et al. Nextgeneration sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet Feb 19
34 GENES AND CANCER SITES
35 FUN FACT #4: I T I S V E R Y U N L I K E LY Y O U W I L L E V E R O R D E R G E N E T I C T E S T I N G F O R A S I N G L E G E N E / C A N C E R S Y N D R O M E
36 CASE #2 COLON POLYPS 57-year old male first colonoscopy at multiple polyps throughout colon -- pathology: tubular adenomas and mucosal polyps with muscle overgrowth follow-up colonoscopy (6 months later) -- multiple polyps in each colon segment -- uncountable polyps in transverse colon -- pathology: tubular adenomas and hyperplastic polyps
37 TESTING STRATEGY genetics evaluation if >10 adenomas present, test for FAP / MAP conventional approach: -- sequencing and rearrangement testing of APC, MUTYH genes -- if polyp NOT adenomatous, assess whether patient meets NCCN criteria for less common polyposis syndrome, such as Cowden, Peutz-Jehger, or Juvenile Polyposis syndrome.
38 COLORECTAL CANCER Sporadic (70%) FAP = Familial adenomatous polyposis MAP= MUTYH-associated polyposis Familial (25%) - Lynch syndrome (3%) - FAP (1%) - MAP (1%) - Rare CRC syndromes (<1%) juvenile polyposis Peutz-Jehgers syndrome serrated polyposis PTEN-related syndrome hereditary diffuse gastric cancer (HDGC)
39 LIFETIME RISKS FOR COLORECTAL CANCER Cancer Risk (%) FAP AFAP MAP General Population
40 APC / MUTYH negative NOW
41 COLONEXT NGS PANEL (AMBRY) Gene Syndrome CRC Risk Polyposis Other Associated Cancer(s) STK11 Peutz-Jeghers Up to 40% Yes Breast, pancreas, GI, uterine, cervical CHEK2 CDH1 Hereditary Breast/CRC Hereditary Diffuse Gastric Cancer Increased No Breast Increased No Lobular breast, diffuse gastric PTEN Cowden Increased Yes Breast, thyroid, kidney, uterine TP53 Li-Fraumeni Increased No Breast, sarcoma, brain, leukemia MYH MAP Up to 80% Yes Duodenal, thyroid APC FAP / AFAP Up to 99% Yes Duodenal, thyroid MLH1 MSH2 MSH6 PMS2 EPCAM Lynch Up to 80% No Stomach, brain, Uterine, ovarian, Pancreas, ureter SMAD4 BMPR1A Juvenile Polyposis Up to 50% Yes Stomach
42 THINGS TO CONSIDER BEFORE TESTING - CLINICIAN Gene / syndrome-specific testing is still available and MAY be a reasonable option in some cases and should be discussed with any patient MSI / IHC should be utilized when Lynch syndrome is suspected Large gene panels can take several weeks to several months for results Large panels may not be feasible when making time-sensitive decisions
43 THINGS TO CONSIDER BEFORE TESTING - PATIENT Longer turnaround time may delay treatment / surgery Testing may find variants with unclear cancer implications Testing may find variants revealing risk for unrelated cancers Results may have implications for other family members
44
45 PTEN HAMARTOMA TUMOR SYNDROME (PHTS) Includes: Cowden syndrome, Proteus syndrome, Bannayan-Riley-Ruvalcaba syndrome (BRRS) Thyroid cancer (35%) Kidney cancer (33%) Colorectal cancer (9%) Melanoma (6%) Breast cancer (60%) Endometrial cancer (28%) Uterine fibroids Hamartomatous polyps Macrocephaly Thyroid nodules, goiter Trichilemmomas, papillomatous papules Hyperpigmentation Overgrowth Fibrocystic breast disease Autism spectrum disorder Mental retardation (IQ<75) Lipomas
46 Lipomas, HC 63.9 cm Asperger syndrome macrocephaly LD autism
47 PTEN HAMARTOMA TUMOR SYNDROME (PHTS) Includes: Cowden syndrome, Proteus syndrome, Bannayan-Riley-Ruvalcaba syndrome (BRRS) Thyroid cancer (35%) Kidney cancer (33%) Colorectal cancer (9%) Melanoma (6%) Breast cancer (60%) Endometrial cancer (28%) Uterine fibroids Hamartomatous polyps Macrocephaly Thyroid nodules, goiter Trichilemmomas, papillomatous papules Hyperpigmentation Overgrowth Fibrocystic breast disease Autism spectrum disorder Mental retardation (IQ<75) Lipomas VARIABLE EXPRESSIVITY
48 PTEN WORKUP - JW Subtotal colectomy with IRA path: colon with multiple tubular adenomas and hamartomatous polyps Double balloon enteroscopy -- glycogenic acanthosis, ileal and jejunal polyps Thyroid ultrasound innumerable nodules Recommendations: Yearly physical Yearly thyroid ultrasound Yearly derm exam Continue GI screening based on polyp burden Genetic testing for first degree relatives > age 18 Derm exam unremarkable MRI of the abdomen unremarkable
49 CASE #3 - HBOC 46 year old woman with a newly diagnosed left breast cancer ER/PR+ invasive ductal carcinoma Referred for genetic risk assessment by patient request -- wants risk estimate to help her decide about bilateral mastectomy
50 CANCER RISKS IN HBOC BRCA1 Breast cancer: 54-90% 2nd breast cancer: 27% within 5 years Ovarian cancer: 24-40% BRCA2 Breast cancer: 41-87% 2nd Breast cancer: 12% within 5 years Ovarian cancer: %
51 CANCER RISKS IN HBOC
52 FUN FACT #5 A LWAY S A S K A B O U T B O T H S I D E S O F T H E FA M I LY W H E N TA K I N G A FA M I LY H I S T O R Y!
53 CASE #3 PEDIGREE
54 MYRISK (MYRIAD) RESULTS
55 BOOM! POSITIVE TEST! Deleterious variant - MUTYH gene c.1187g>a (p.gly396asp)
56 MUTYH GENE involved in base excision repair germline MUTYH mutations impair DNA repair of somatic APC mutations leading to a phenotype similar to FAP RECESSIVE inheritance biallelic carriers are predisposed to: Multiple colorectal adenomas upper GI manifestations stomach cancer, duodenal polyps Early onset colon caner CHRPE Risks for other cancers is unclear (possible increased risk for breast cancer, skin cancer, ovarian cancer)
57 MUTYH-ASSOCIATED POLYPOSIS MUTYH testing classically bundled with APC accounts for 1% of all CRC accounts for up to 3% of CRC under age 50 monoallelic carriers: - studies conflict on whether cancer risk is increased - carrier rate: 1-2% of the general US population
58 SO, IN OTHER WORDS Does she have a disease-causing variant? YES. Does it explain her cancer? NO. Does this variant, on its own, affect her risk for cancer? Probably not.
59
60
61 MYRISK RESULTS Deleterious variant - MUTYH gene c.1187g>a (p.gly396asp) Variants of Uncertain Significance (VUS) - BRCA2 c.8447g>a (p.gly2816asp) - STK11 c.1062c>g (p.phe354leu)
62 FUN FACT #6: S O M E T I M E S I N O U R Q U E S T F O R A N S W E R S W E O N LY F I N D M O R E Q U E S T I O N S.
63 VARIANT INTERPRETATION Citation: Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J.,... & Voelkerding, K. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. Medical mgmt. based on personal & family hx. Uncertain results do not influence recommendations for care. Medical mgmt. based on guidelines for gene variant and its associated syndrome(s).
64 RATES OF UNCERTAIN VARIANTS 40.0% Decline in Rate of BRCA1/2 Variants of Uncertain Significance 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% All Patients Middle Eastern Asian African Native American Latin American Central European Western European 5.0% 0.0% Eggington et. al. Current Variant of Uncertain Significance Rates in BRCA1/2 and Lynch Syndrome Testing (MLH1, MSH2, MSH6, PMS2, EPCAM), March 2012, ACMG Poster Presentation.
65 CASE #3 PEDIGREE MUTYH-positive VUS BRCA2 VUS STK11 NO BRCA2 VUS
66 STK11 GENE associated with Peutz-Jehgers syndrome autosomal dominant ~50% de novo characteristic hyperpigmentation of the mucosa hamartomatous polyps
67 CANCER RISKS IN PJS Breast - 50% Colorectal - 39% Pancreatic 11-36% Gastric - 29% Small bowel 13% Ovarian - 21% Cervical 10% Uterine - 9% Lung - 15% Testicular -?
68 RECOMMENDATIONS currently no genetic indication that PR s risk for a second breast cancer is significantly increased. recommended standard breast treatment, screening, and follow-up care based on physician recommendations and family history undergo colonoscopy every 5 years MYH testing recommended for 1 st degree relatives -- to assess for MAP -- high US carrier rate (1-2%)
69 THIS CASE ILLUSTRATES complex inheritance patterns with some syndromes significant risk of variants of uncertain significance - approximately one-third of panel results - newer genes, less literature, smaller samples - reclassification of many VUS with time challenges for clinicians in sorting out the data challenges for patients trying to make decisions about care
70 FUN FACT #7: Y O U D O N T N E E D T O K N O W E V E R Y T H I N G. Y O U D O N E E D T O K N O W W H E N T O R E F E R.
71 A GENETIC COUNSELOR CAN HELP YOU RIGHT PATIENT RIGHT TEST RIGHT LAB RIGHT RESULTS
72 WHEN TO REFER TO GENETICS triple-negative breast cancer male breast cancer ovarian cancer young onset (< 50) same/related cancer in relatives autosomal dominant inheritance with rare exceptions aggressive prostate cancer - Gleason score 7 multiple primaries multifocal / bilateral cancers rare cancers unusual non-malignant features (i.e., syndromic ) confirmed mutation in relative If uncertain, refer anyway!
73 LAST FUN FACT: G E N E T I C S A N D O U R U N D E R S TA N D I N G O F M U TAT I O N S I S E V O LV I N G, S O T O D AY S G E N E T I C R E S U LT M U S T A L W AY S B E R E A S S E S S E D A N D I N T E R P R E T E D B A S E D O N C U R R E N T I N F O R M A T I O N A N D S T U D I E S O F M O D I F I E R S, P R O P H Y L A X I S O P T I O N S, A N D P R E V E N T I O N. M I C H A E L H A L L, M D F O X C H A S E C A N C E R C E N T E R P H I L A D E L P H I A, P A
74 QUESTIONS? My contact information: Carla Bell, MS, LCGC Wesley Medical Center Oncology Department 550 North Hillside Wichita, KS Direct phone: Fax:
Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationPrior Authorization. Additional Information:
Genetic Testing for Cowden Syndrome - PTEN Gene MP9488 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic
More informationGI EMERGENCIES Acute Abdominal Pain
GI EMERGENCIES Acute Abdominal Pain Marcia Cruz-Correa, MD, PhD, AGAF. FASGE Associate Professor of Medicine, Biochemistry, Surgery Director Translational Research University of Puerto Rico Comprehensive
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationA Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationHEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK
HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK OCTOBER 20, 2017 JESSICA CARY, MS, RN, CGC cary@newecs.org GENETIC COUNSELOR OBJECTIVES 1) Taking a Cancer Family History 2) Identify patients and/or
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationBowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:
BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK. Unfortunately 1 in 19 women and 1 in 14 men will develop
More informationGHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene
GHUK BowelGene_2017.qxp_Layout 1 22/02/2017 10:22 Page 3 BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK.
More informationObjectives. Genetics in Cancer Treatment and Prevention. Genes
Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology
More informationPathology reports, related operative reports and consult letters must be provided with a request for assessment.
Page 1 of 6 Polyposis Syndromes Inherited risk for colorectal cancer is associated with a number of polyposis syndromes (genes), some of which are well-defined and others are less common. Identification
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationHereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD
Hereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD Living Beyond Cancer A-Z January 12,2019 Hereditary CRC Syndromes Objectives are to discuss the : Most common Hereditary CRC syndromes
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Syngal, MD, MPH, FACG, 1,2,3 Randall E. Brand, MD, FACG, 4 James M. Church, MD, FACG, 5,6,7
More informationHereditary GI tumor syndromes ACG guidelines of genetic testing and management. Dr. med. Henrik Csaba Horváth PhD
Hereditary GI tumor syndromes ACG guidelines of genetic testing and management Dr. med. Henrik Csaba Horváth PhD Genetic testing and management of hereditary GI tumor syndromes June 29, 2016 2 Clinical
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationWhat All of Us Should Know About Cancer and Genetics
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
More informationResult Navigator. Positive Test Result: PTEN. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: PTEN Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14, 09/15/15.
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationA Patient s Guide to risk assessment. Hereditary Colorectal Cancer
A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? Overview of Syndromes This workbook is designed to help you decide if hereditary cancer
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationPathology perspective of colonic polyposis syndromes
Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationFamilial Adenomatous Polyposis
Familial Adenomatous Polyposis 1 in 10,000 incidence 100 s to 1000 s of colonic adenomas by teens Cancer risk: colon, gastric, duodenum (periampulla), small bowel, pancreas, papillary thyroid, childhood
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationGI Polyp syndromes in children. Screening and surveillance, surgery.
Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital, UK GI Polyp syndromes in children Screening and surveillance, surgery. No conflict of interests to declare Objectives Understand
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2019 Origination: 1/2004 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationNGS for Cancer Predisposition
NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationColorectal Cancer Syndromes. Barbara Jung, MD AGAF Associate Professor and Chief University of Illinois at Chicago
Colorectal Cancer Syndromes Barbara Jung, MD AGAF Associate Professor and Chief University of Illinois at Chicago Outline Colon cancer General Genetics, Risk, Screening Specific Syndromes, when to suspect,
More informationMedical Policy Update
Medical Policy Update Summer 2017 Highlights of recent medical policy revisions as well as any new medical policies approved by Prevea360 Health Plan s Medical Policy Committee are shown below. The Medical
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationGenetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
More informationThe Genetics of Familial Polyposis
The Genetics of Familial Polyposis Thursday, September 24 th 2015 Kara Semotiuk, MS, (C)CGC & Laura Winter, MSc, CGC Genetic Counsellors at the FGICR Familial Polyposis Familial Can run in the family related
More informationCowden Syndrome PTEN Hamartoma Tumor Syndrome. ACCME/Disclosure. 1. Background. Outline
MASSACHUSETTS GENERAL HOSPITAL HARVARD MEDICAL SCHOOL PATHOLOGY Cowden Syndrome PTEN Hamartoma Tumor Syndrome ACCME/Disclosure Vania Nosé, MD, PhD Professor of Pathology Director of Anatomic Pathology
More informationPrior Authorization. Additional Information:
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationWELCOME. Taking Care of Your Health. April 30, 8 am to noon
WELCOME Taking Care of Your Health April 30, 8 am to noon Cancer: Know Your Risk Emily Kuchinsky, MS, CGC, Certified Genetic Counselor Sporadic Cancer Lifetime Probability- Women Family Cluster Risk factors
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationClassification of polyposis syndromes two major groups. Adenomatous polyposis syndromes. Hamartomatous polyposis syndromes
Hereditary polyposis syndromes Classification of polyposis syndromes two major groups adenomatous and non-adenomatous polyposis syndromes Adenomatous polyposis syndromes Familial adenomatous polyposis(fap)
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14 REVISED DATE: 10/15/15, 10/20/16, 01/18/18
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY REVISED DATE: 10/15/15, 10/20/16, 01/18/18 PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationHereditary Colorectal Cancer
A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationColorectal Cancer and Hereditary Colon Cancer Syndromes Carol A. Burke, M.D.
Colorectal Cancer and Hereditary, FACG, FACP Sanford R. Weiss MD Center for Hereditary Colorectal Neoplasia Digestive Disease Institute Cleveland Clinic, Cleveland, Ohio 1 Objectives Review the molecular
More informationPage 1 of 8 TABLE OF CONTENTS
Page 1 of 8 TABLE OF CONTENTS Patient Evaluation and Recommendation..Page 2 Testing and Follow-up..Page 3 Genetic Counseling Referral Criteria.....Page 4-5 Patient Education..Page 6 Suggested Readings...Page
More informationGeneHealth BreastGene_New qxp_Layout 1 21/02/ :42 Page 3 BreastGene GeneHealth UK
GeneHealth BreastGene_New 8.2.17.qxp_Layout 1 21/02/2017 16:42 Page 3 BreastGene GeneHealth UK BreastGene What is hereditary breast cancer? Breast cancer is the most common cancer in the UK. Unfortunately
More informationBreast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center
Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More informationWHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016
WHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016 39 th Annual CANP Educational Conference March 17 20, 2016 Collaborate. Educate. Advocate. Karen Herold, DNP,
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationCorporate Medical Policy
Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationAdenomatous Polyposis Syndromes (FAP/AFAP and MAP)
A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer
More information